|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:antidote
|
gptkb:flumazenil
|
|
gptkbp:approvalYear
|
1963
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05BA01
|
|
gptkbp:brand
|
gptkb:Valium
|
|
gptkbp:CASNumber
|
439-14-5
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
severe respiratory insufficiency
sleep apnea syndrome
severe hepatic insufficiency
|
|
gptkbp:cost
|
inexpensive
|
|
gptkbp:developedBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:discoveredBy
|
gptkb:Leo_Sternbach
|
|
gptkbp:eliminationHalfLife
|
20-100 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C16H13ClN2O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Diazepam
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1963
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:riskOfOverdose
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
rectal
|
|
gptkbp:sideEffect
|
confusion
fatigue
muscle weakness
drowsiness
ataxia
dependence
|
|
gptkbp:synonym
|
7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
|
|
gptkbp:UNDrugSchedule
|
gptkb:Schedule_IV_(US_Controlled_Substances_Act)
|
|
gptkbp:usedFor
|
gptkb:alcohol_withdrawal_syndrome
seizures
anxiety disorders
muscle spasms
sedation before medical procedures
|
|
gptkbp:usedIn
|
gptkb:restless_legs_syndrome
tetanus
status epilepticus
panic attacks
preoperative sedation
acute repetitive seizures
insomnia (short-term)
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Schedule_IV
gptkb:Benzodiazepines
|
|
gptkbp:bfsLayer
|
6
|